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Background: Aviscumine, a recombinant plant protein, is an immune modulator that induces ribotoxic stress at
the 28S ribosomal RNA subunit. In this way cytokine release and T-cell responses are enhanced. This phase II trial
was conducted to test the efficacy and safety of aviscumine in patients with systemically pre-treated metastatic
melanoma stage IV.
Methods: A total of 32 patients with progressive stage IV melanoma after failure of standard therapy were enrolled
onto a single-arm, multi-centre, open-label, phase II trial. All patients had an ECOG performance status of 0 or 1.
Patients received 350 ng aviscumine twice weekly by subcutaneous injection until progression. The primary end
points were progression-free survival (PFS) and overall survival (OS). Safety was assessed as adverse events (AEs).
Tumor response was assessed every eight weeks and survival of patients was followed up to one year after the end
of therapy. Thirty one patients (intent-to-treat population (ITT)) were assessed for efficacy; safety was assessed in
the whole population.
Results: One patient achieved a partial response (PR) and 10 patients showed stable disease/no change (SD). The
median progression-free survival (mPFS) was 63 days (95% CI 57–85) and median overall survival (mOS) was 335
days (95% CI 210–604). In total 210 treatment-emergent adverse events were recorded. Grade 1 or 2 AEs occurred
in 72% of patients and were mostly application-site effects such as pruritus Grade 3–4 treatment-emergent
drug-related adverse events occurred in 9% of patients.
Conclusion: These results suggest that aviscumine may have a clinical impact in patients with previously treated
metastatic melanoma and provide rationale for further clinical evaluation of this agent. In the light of effective new
immune checkpoint blockers it might be a candidate for combinations with these agents.
Trial registration: ClinicalTrials.gov: NCT00658437
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Ribosome-inactivating proteinBackground
Cutaneous malignant melanoma causes a small number of
skin cancers but leads to nearly 80% of skin cancer deaths
[1]. Annually, there are worldwide around 160,000 new
cases of malignant melanoma with 41,000 deaths and it
has the fastest rising incidence of all skin cancers among
men and the second-fastest among women — which is* Correspondence: h.lentzen@gmx.de
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unless otherwise stated.predicted to continue [2]. Prognosis for patients with stage
IV metastatic melanoma is poor [3]. In a meta-analysis of
42 phase II trials, median survival was only 6.2 months,
with a 1-year survival rate of 25.5% regardless of treatment
regimen [4].
Dacarbazine (DTIC), the only chemotherapeutic agent
approved in the US and in Europe for the treatment of
metastatic melanoma, is associated with a response rate of
5–12% and a median overall survival of 5.6 to 9.1 months
after the initiation of therapy [5-11].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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many studies have evaluated the combination of chemo-
therapy with immunotherapy, particularly regimens con-
taining interferon alfa and interleukin-2 (IL-2) [15].
These biochemotherapeutic approaches increase response
rates but could not improve survival [16-18]. Also mono-
immunotherapy with high dose IL-2 has never been
shown to significantly prolong survival in phase III trials
in patients with advanced stage IV melanoma [19,20]. In
addition, IL-2 treatment-related toxicity is severe and
often requires inpatient intensive care [21-23].
However, monotherapy with ipilimumab, a fully hu-
man monoclonal antibody (IgG1) that blocks CTLA-4 to
promote antitumor immunity, has shown meaningful
clinical activity including an improvement of overall sur-
vival in patients with metastatic melanoma in phase II
and III studies [11,24-27].
Approximately 40 to 60% of cutaneous melanomas carry
mutations in BRAF that lead to constitutive activation of
downstream signalling through the MAPK pathway [28,29].
Therefore, treatment with selective BRAF and MEK in-
hibitors is restricted to patients with mutation-positive
melanomas. Recently a phase III randomized clinical
trial comparing vemurafenib, a potent inhibitor of mu-
tated BRAF [30], with DTIC in patients with previously
untreated, metastatic melanoma with a BRAF V600 muta-
tion has shown improved rates of overall and progression-
free survival for vemurafenib [31]. Moreover, a phase III
randomized clinical trial of previously untreated BRAF
V600E mutated melanoma patients compared dabrafenib
to dacarbazine and demonstrated improvements in RR (50
vs. 6%) and PFS (5.1 vs. 2.7 months) [32]. Treatment of a
similar patient population with the MEK inhibitor trameti-
nib in those who had not previously received a BRAF in-
hibitor resulted in a median overall survival of 14.2 months
and estimated 1-year survival of 59% [33].
Aviscumine, a recombinant plant protein, is a class II
ribosome-inactivating protein. The drug preferentially and
specifically binds to cell-surface structures containing
CD75s (α2,6 sialolactosamine) [34-36]. CD75s structures
are over-expressed in solid tumour cells [37,38], in im-
mune cells (e.g. granulocytes, monocytes/macrophages,
B-cells) and in endothelial cells as well as in epithelial cells
[39-43]. Binding enables internalisation of the drug and
subsequent selective cleavage of the N-glycosidic bond of
the adenine-4324 residue in the eukaryotic 28S ribosomal
RNA, thus inducing catalytic inactivation of the ribosomes
and inhibition of protein synthesis (“ribotoxic stress”) [44].
The “ribotoxic stress” induces T-cell responses, activation
of natural killer cells, and antigen-presenting cells (APCs)
(e.g. monocytes/macrophages, dendritic cells), and stimu-
lation of cytokine release [45,46]. IL-1β and IFN-γ seem to
be the most relevant cytokines. The disease stabilisation in
patients with advanced cancer observed in a phase I trialwas associated with an increase of plasma levels of IL-1β
and IFN-γ [47].
Here we report results from a single-arm, multi-centre,
open-label, phase II trial to investigate the efficacy and
safety of subcutaneously administered aviscumine (CY-503)
monotherapy in patients with unresectable stage IV meta-
static melanoma after failure of one or more previous anti-
neoplastic therapies.
Results
Between April 2008 and May 2009 32 pretreated pa-
tients with confirmed metastatic melanoma (stage IV)
were included in the study. Baseline characteristics are
shown in Table 1. Characteristics of patients, which are
known to be prognostic in stage IV melanoma patients
(age, sex, stage, and LDH), were well balanced. For effi-
cacy analyses, 31 patients met the eligibility criteria and
were evaluated as the ITT population.
The mean duration of treatment was 104.7 (SD 98.0)
days. Patients received a mean of 6.2 (range 1–8) injec-
tions per cycle and 25.6 injections (range 1–127) overall.
The most frequent reason for discontinuation of therapy
was disease progression. 10 patients (32.3%) had stable
disease during the study, one patient showed partial re-
sponse. The disease control rate (DCR) was 35.5% (11 of
31 patients) (Table 2). Median PFS was 63 days (95% CI
57–85).
Kaplan-Meier analysis of OS was conducted. The ob-
served mOS was 335 days (95% CI 210–604) (Figure 1).
Using a benchmark analysis according to Korn [4] the pre-
dicted mOS was 256 days (95% CI 155–378). The pre-
dicted 1-year survival rate was 33.1% (95% CI 16.5-49.7)
(historical 1-year OS) [4] in comparison to the observed
1-year survival rate of 45.0% (95% CI 29.8–60.2). The haz-
ard ratio for death was 0.75 (95% CI 0.42-1.36), indicating
a possible survival benefit in this study.
mOS data and 1-year-survival rates were analysed
among patient subgroups (Table 3). There was no differ-
ence in mOS and 1-year survival rates between ECOG 0
and ECOG 1 subgroups or in the pretreatment groups.
However, females showed a tendency to better 1-year
survival (53.3%) as compared to males (36.4%). Patients
showing disease control exhibited mOS of 14.3 months
and a 1-year survival rate of 72.7% (Table 3). Interestingly,
patients with an induced injection site reaction showed a
longer survival (mOS: 445 days, 95% CI: 335–604) com-
pared to patients without induced injection site reactions
(mOS: 155 days, 95% CI: 67–210).
The safety population (32 patients) included all pa-
tients who had undergone randomization and who
had received any amount of study drug. In total 210
AEs were recorded between the first dose and 30 days
after the last dose of aviscumine. All 32 patients experi-
enced at least one AE. The most frequent AEs were
Table 1 Demographic and clinical characteristics of
patients at baseline












Visceral metastases 28 (87.5%)
Non visceral metastases 4 (12.5%)
LDH level
</=Upper limit of the normal range 18 (56.3%)
> Upper limit of the normal range 14 (43.8%)








Other anticancer therapy*** 8 (25.0%)
Data are number (%) or mean. *Carboplatin, Cisplatin, DTIC, Fotemustine,
Gemcitabine, Melphalan, Paclitaxel, Treosulfan, Vindesine, **IFN, Ipilimumab,
Thymosin, ***CNTO, Genasense, Imatinib, Sorafenib, STA-4783-08.
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(27.6%) AEs in 24 patients were deemed probably, pos-
sibly or certainly related to the study drug. Of these,
most were NCI CTCAE grade 1 or grade 2; 8 (13.8%)
were grade 3–4 events (Table 4).Table 2 Overall response and disease control rates (ITT
population)




Stable disease 10 (32.3%)
Progressive disease 19 (61.3%)
Not determinable 1 (3.2%)
Disease control rate† 11 (35.5%)
*Summary from site and central review; †Calculated as (complete response +
partial response + stable disease)/number of patients.Twelve SAEs occurred in five (16%) of 32 patients.
Two patients died from dyspnoea and tachyarrhythmia,
respectively, but these events were not deemed to be re-
lated to the study drug. The other three patients had
thrombocytopenia, cerebral ischaemia (both CTCAE
grade 4), chest pain (CTCAE grade 3) and atrial fibrilla-
tion, dehydration, pneumonia, venous thrombosis, urin-
ary tract infection and urosepsis (all CTCAE grade 3).
IgG and IgM anti-aviscumine antibody data were avail-
able for 29 patients. All except two patients developed
IgG anti-aviscumine antibodies of different strength
during the trial. One additional patient had an anti-
aviscumine IgG antibody titer at baseline. The titers
were in the range 11 – 1,690 μg/mL. Furthermore most
of the patients with IgG antibody titer showed also an
IgM titer. A correlation between anti-aviscumine anti-
body titers and PFS and OS, respectively, could not be
detected (Cox regression analysis for PFS and OS, re-
spectively: p > 0.05).
Discussion
Aviscumine treatment at a dose of 350 ng resulted in a
median overall survival of 11 months and a 1-year sur-
vival rate of 45% in patients with unresectable metastatic
malignant stage IV melanoma who had undergone previ-
ous treatment. The 1-year survival rate regarded as a key
benchmark for comparing efficacy of novel therapeutics
versus historical data is notably higher than the pre-
dicted value of 33.1% [4]. More than 70% of the patients
had M1c disease indicating the presence of visceral me-
tastasis, and more than 50% had elevated lactate de-
hydrogenase levels, both of which are associated with
very poor survival [4,48].
The hazard ratio for death is 0.75 (95% CI 0.42-1.36) in-
dicating a possible survival benefit in the aviscumine study
compared with historical data of Korn et al. [4]. Also the
median overall survival in our study (11 months) com-
pares favorably with 8.4 months from a historical survival
curve [4]. Nevertheless we have to state that the numbers
enrolled are small.
In a phase II trial of sorafenib with temsirolimus (arm
a) or tipifarnib (arm b) in untreated metastatic melan-
oma patients the median OS was 7 months in both
treatment arms, while the number of patients achieving
an objective response was seen in 4.7% and 2.6%, re-
spectively [49]. Ipilimumab (3 mg/kg), an anti-CTLA4
antibody, showed a 1-year survival rate of 39.3% and a
median OS of 8.7 months in a phase II trial with 50%
M1c patients [26].
In recent randomized, phase III trials involving pa-
tients with unresectable stage III or IV melanoma who
had received previous treatment, 1-year survival rates
were reported to be 22% to 38% with various treatment
regimens [50,51]. The median overall survival in these
Figure 1 Kaplan–Meier estimates of overall survival by ITT population О censored numbers.
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nor other randomized, controlled trials had shown a sig-
nificant improvement in overall survival.
However, ipilimumab was shown in two phase III, ran-
domized, controlled trials to increase the survival in pa-
tients with unresectable metastatic melanoma (stage III






Overall 11.0 (6.9 – 19.8) 45.0 13/29
Gender
Female 13.9 (6.9 – 19.8) 53.3 8/15
Male 8.7 (4.7 – 14.6) 36.4 5/14
Performance status
ECOG 0 10.8 (6.9 – 19.8) 43.8 7/16
ECOG 1 11.0 (5.1 – 19.8) 46.8 6/13
Metastasis stage
M1a 14.6 (10.3 – 14.6) 66.7 2/3
M1b 19.8 (1.2 – 19.8) 75.0 3/4
M1c 8.8 (6.3 – 14.3) 36.4 8/22
Age
≤60 years 9.8 (6.4 – 14.6) 30.0 3/10
>60 years 13.9 (6.3 – 19.8) 53.1 10/19
Pre-treatment
1 11.3 (6.9 - 13.9) 46.9 7/15
≥2 10.0 (5.1 – 14.6) 42.9 6/14
Patients
Non-progressive 14.2 (11.3 – 19.8) 72.7 8/11
Progressive 8.4 (5.1 – 11.0) 28.1 5/18
OS = overall survival, ITT = intention to treat, CI confidence interval.10.0 months [27] or with DTIC from 9.1 to 11.2 months
[11]. Compared with the vaccine the 1-year survival rate
was 45.6%, but there was only a modest effect on rates
of response and progression-free survival [27]. The use
of ipilimumab combined with DTIC in patients with
unresectable metastatic melanoma (stage III and IV) has
also been associated with improved rates of survival over
DTIC alone [11]. The 1-year survival rate in the first-
line treated ipilimumab/DTIC arm was 47.3% and in the
first-line placebo plus DTIC arm was 36.3% [11].
In the context of published clinical experience with
comparable patient populations, the 1-year overall sur-
vival rate of 62% and a median overall survival of
16.8 months associated with nivolumab, an immune
checkpoint blocker of the anti-PD-1 antibody type, are
particularly important [52].
Clinical activity of aviscumine was observed in all sub-
groups of patients, including patients with stage M1c
disease. It was also seen both in ECOG 0 or in ECOG 1
patients. The median overall survival was 10.8 months
vs. 11.0 months and the 1-year survival rate was 44% vs.
47% . This finding is interesting due to the known asso-
ciation between performance status and overall survival
and the inclusion of the performance status as an im-
portant prognostic factor for stage IV melanoma patients
[4,53]. The predicted 1-year overall survival rate for pa-
tients with visceral disease (M1b and M1c) was 23.8%
[4] in comparison to 42.3% in this study.
The median progression-free survival was 63 days and
was not different to standard therapy. Also Hodi re-
ported only a modest effect on rates of response and
progression-free survival for the immunotherapeutic ipi-
limumab [27]. Regarding the immunotherapeutic ap-
proaches it is discussed that conventional definition of
disease progression incompletely reflects the survival
benefit [54,55].
Table 4 Drug-related adverse events (n = 58) for safety population (n = 32)
Adverse effect Grade
1 n (%) 2 3 4 Total
n (%) n (%) n (%) n (%) n (%)
Application site erythema 2 (6.3) 1 (3.1) - - 3 (9.4)
Application site pain 1 (3.1) 1 (3.1) - - 2 (6.3)
Application site pruritus 1 (3.1) 1 (3.1) - - 2 (6.3)
Application site rash 1 (3.1) - - - 1 (3.1)
Application site reaction 9 (28.1) 5 (15.6) - - 14 (43.8)
Application site swelling 1 (3.1) 1 (3.1)
Cerebral ischaemia - - - 1 (3.1) 1 (3.1)
Chills 1 (3.1) - - - 1 (3.1)
Decreased appetite - 1 (3.1) - - 1 (3.1)
Diarrhoea 1 (3.1) - - - 1 (3.1)
Dizziness 1 (3.1) - - - 1 (3.1)
Drug eruption 1 (3.1) 1 (3.1) - - 2 (6.3)
Dry mouth 1 (3.1) - - - 1 (3.1)
Dyspnoea - - - 1 (3.1) 1 (3.1)
Erythema 1 (3.1) - - - 1 (3.1)
Fatigue 3 (9.4) - - - 3 (9.4)
Headache 1 (3.1) - - - 1 (3.1)
Hyperglycaemia - - 1 (3.1) - 1 (3.1)
Leukopenia - - - 1 (3.1) 1 (3.1)
Musculoskeletal discomfort 1 (3.1) - - - 1 (3.1)
Nasopharyngitis 1 (3.1) - - - 1 (3.1)
Nausea - 1 (3.1) - - 1 (3.1)
Neutropenia - - - 1 (3.1) 1 (3.1)
Night sweats 1 (3.1) - - - 1 (3.1)
Oedema peripheral - 1 (3.1) - - 1 (3.1)
Pruritus 4 (12.5) - 1 (3.1) - 5 (15.6)
Pyrexia 2 (6.3) - - - 2 (6.3)
Thrombocytopenia - - - 1 (3.1) 1 (3.1)
Venous thrombosis - - 1 (3.1) - 1 (3.1)
Vision blurred 1 (3.1) - - - 1 (3.1)
Vulvovaginal mycotic infection 1 (3.1) - - - 1 (3.1)
Weight decreased - 1 (3.1) - - 1 (3.1)
Weight increased 1 (3.1) - - - 1 (3.1)
Terms are from MedDRA (version 14.0) preferred terms, and grades are Common Toxicity Criteria of the National Cancer Institute (version 3.0). The drug-related
adverse events occurred in 24 of 32 treated patients.
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met the criteria for a confirmed disease control (SD,
PR), whereby most patients had SD. The high rate of
SD may be viewed as an indicator of a meaningful thera-
peutic effect. Disease control due to SD is characteris-
tic for immunotherapeutics and other biologics in
cancer [54]. For example in a recent phase II combin-
ation trial of dendritic cell vaccination, interleukin-2and metronomic cyclophosphamide the median OS
was 9.4 months, while none of the patients achieved
an objective response, but 57% of the patients achieved
stable disease (SD) [56].
The confirmed DCR in our study is slightly higher
than the DCR of 28.5% and 33.2% in the ipilimumab
phase III trials [11,27]. Even in the EORTC phase I trial
of aviscumine to treat solid malignant tumors, twice
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weight showed a disease control rate of 31%, lasting from
11.3 to 35.7 weeks [47].
Patients receiving aviscumine reported only 8 drug-
related adverse events grade 3 or 4. These were cerebral
ischaemia, dyspnoea, hyperglycaemia, leukopenia, neu-
tropenia, pruritus, thrombocytopenia and venous throm-
bosis. The majority of drug-related adverse events
(application site reactions, grade 1 or 2) were immune-
related and consistent with the proposed mechanism of
action of aviscumine. The patient with cerebral ischae-
mia started into the trial with known leukopenia and
thrombocytopenia due to previous chemotherapy.
Subcutaneous injection of aviscumine induced anti-
aviscumine antibodies. The induction of these antibodies
did not have any influence on the outcome parameters
disease control rate and survival. Although the mechan-
ism underlying the activity of aviscumine is not fully
understood, it is known that the drug induces a strong
immune response via pleiotropic mechanisms due to ac-
tivation either of the innate or the adaptive immune sys-
tem [45,46].
In conclusion, the relatively high DCR and relatively
long OS in patients with unresectable metastatic melan-
oma (stage IV), the good tolerability of 350 ng aviscu-
mine per injection after failure of dacarbazine or other
previous therapies suggest that larger, randomized, con-
trolled clinical trials also as treatment combinations con-
sidering the immune-related response criteria (irRC)
[54] are now warranted.
Conclusions
Aviscumine treatment at a dose of 350 ng (twice-weekly
subcutaneously injected) resulted in clinical activity in
patients with unresectable metastatic malignant stage IV
melanoma who had undergone previous treatment.
These results provide rationale for further clinical evalu-
ation of this agent. In the light of effective new immune
checkpoint blockers it might be a candidate for combi-
nations with these agents.
Methods
Patients
Patients had to be at least 18 years old, with histologically
confirmed stage IV melanoma with unresectable metasta-
ses and one or more measurable lesions. All patients had
received at least one prior line of anti-neoplastic therapy.
They had Eastern Cooperative Oncology Group (ECOG)
performance status 0 or 1, LDH ≤2.5 ULN, serum creatin-
ine levels ≤1.5 mg/dL, absolute neutrophil count ≥1.5 ×
109/L, platelet count ≥100 × 109/L, and life expectancy
≥3 months. Patients had measurable disease according to
Response Evaluation Criteria In Solid Tumors (RECIST)
guidelines [57]. Exclusion criteria included pretreatmentwith mistletoe extracts, CNS metastasis, and ocular or
mucosal melanoma.
Study design
The study was conducted at 4 centres in Germany be-
tween April 2008 and May 2010. Patients received
twice-weekly subcutaneous injections of 350 ng aviscu-
mine in 1 mL solution in the thigh or abdomen. Injec-
tions were done on the same 2 days of each week
(4 weeks = 1 cycle), at least 3 days apart (e.g., Monday
and Thursday, Tuesday and Friday).
Blood for analysis of anti-aviscumine antibodies was
taken at baseline, at the end of every cycle and at the
end of therapy. Anti-aviscumine antibodies (IgG and
IgM) were measured with an ELISA using monoclonal
anti-aviscumine antibody clone 36 (mouse, Cytavis Bio-
Pharma) and aviscumine bound to the titer plate. Detec-
tion was performed with anti-human IgG-POD and
anti-human IgM-POD (both goat, Sigma-Aldrich) and
colour reaction with TMB (Dako). Quantification of
antibodies was performed in relation to standards:
human IgG (Sigma-Aldrich), human IgM (Millipore).
Treatment was scheduled to continue without pause
until disease progression (increase ≥20% in the sum of the
longest diameters of the target lesions and/or new lesions)
or a withdrawal criterion occurred. Withdrawal criteria
were as follows: pregnancy or decision to become preg-
nant; toxic effects potentially related to the study drug
that required discontinuation (≥grade 3 hypersensitivity
and haematological or non-haematological reactions con-
firmed after 48 h); and other contraindication events
(eg. illnesses or complications).
Supportive care and treatment of AEs were left to the
investigator’s discretion. Corticosteroids, immunostimulat-
ing substances and/or monoclonal antibodies were not
allowed except for in life-threatening situations, when cor-
ticosteroids and colony-stimulating factors could be used.
Antiemetics could be used if appropriate. Other antican-
cer agents were not allowed.
The study was carried out in compliance with current
Good Clinical Practice, Ethics Committee recommenda-
tions, informed consent regulations, the Declaration of
Helsinki [58] and with the laws and regulations of
Germany. Approval was received from the local ethics
committee and from the German health authority before
recruitment started. All patients gave their written in-
formed consent.
Study outcomes
The primary end points were overall survival (OS) and
progression-free survival (PFS). OS was defined as time
elapsed from random assignment to death from any cause.
PFS was defined as time elapsed from random assignment
to disease progression, or death, or start of new antitumor
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baseline and every 8 weeks (2 cycles) according to RECIST
guidelines. Independent evaluation of tumor images was
performed by Institut f. Diagnostische u. Interventionelle
Radiologie, Universitätsklinikum Frankfurt/M., Germany.
Secondary outcomes included disease control (complete
remission (CR), partial remission (PR) or stable disease/no
change (SD)), safety (defined by the occurrence and sever-
ity of AEs), and anti-aviscumine antibodies in blood serum.
Safety and tolerability assessment included observed
AEs, clinical laboratory tests, physical examinations, and
vital sign assessments. MedRA (version 14.0) approved de-
scriptions and assigned grades according to the Common
Toxicity Criteria of the National Cancer Institute (NCI
CTCAE version 3.0) were used. AEs were classified as
treatment-related or unrelated according to investigator
judgement. If an AE occurred more than once, it was
counted only once and given the maximum CTCAE grade.
Statistical analysis
Determination of sample size
Determination of sample size was based on PFS of
3 months. The proportion of patients with stage IV malig-
nant melanoma showing PFS of at least 3 months under
DTIC-based chemotherapy is 20%. Only for the purpose
of sample size planning, the value was increased to 40%
and it was deemed that treatment would be unsuccessful
if PFS at 3 months is ≤15%. Therefore, it was estimated
that 29 eligible patients would be required to reach 80%
statistical power with α = 0.05. 32 patients should be
recruited to allow for 10% dropout of non-evaluable pa-
tients. Simon's two-stage design was employed [59]. If
3-month PFS is over the success threshold (≤15%) in the
first 13 recruited patients the trial will be continued.
Efficacy analysis
31 patients met the eligibility criteria (ITT population)
and were included in the primary efficacy analysis. The
survival of patients was followed for up to 12 months.
OS and PFS were estimated by constructing Kaplan-
Meier curves. Patients lost to follow-up or not progressed
at time of analysis were censored. Median overall survival
(mOS) and median progression-free survival (mPFS) were
deduced from the Kaplan-Meier curves. The 1-y survival
rates were estimated from the individual survival data of
the patients.
The immunological response in respect to the analysis
of anti-aviscumine antibodies was examined using de-
scriptive analysis.
Safety analysis
All patients who had received one or more dose of study
treatment were included in the safety and tolerability
analysis (safety population; n = 32). Treatment-emergentadverse events (AEs) were classified and graded using
National Cancer Institute Terminology Criteria for Ad-
verse Events version 3.0. AEs were also classified accord-
ing to MedRA (version 14.0).
Variability estimates are expressed as standard devi-
ation (SD) or 95% confidence intervals (CI). Categorical
variables are expressed as absolute values and percent-
ages. Survival was estimated with the Kaplan–Meier
product limit estimator, and median (95% CI) survival
times are reported. OS and PFS were calculated from
randomization until the occurrence of the pertinent
event or last observation. The information of death due
to melanoma without documented progressive disease
also qualified for PFS event. Cox’s regression models
were calculated for PFS and OS, with adjustment for
following subgroups: ECOG performance status (0, 1),
grade (no visceral, visceral), sex (male, female), age
(≤60 years, >60 years), number of previous treatments
(<2, ≥2), and patients with disease control (non-progres-
sive, progressive). Survival data were compared with
predicted values calculated for each individual subject
based on the prognostic variables included in the meta-
analysis of Korn et al. [4] using the group of trials that
excluded brain metastases. Survival analyses were made
in the intention-to-treat (ITT) population and safety
was assessed in all patients. Fisher’s exact test was used
to calculate two-sided significance values, with p < 0.05
deemed significant.
This study has not been previously presented in full or
in part elsewhere.
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